tirzepatide at the same time as hormone therapy Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review Tirzepatide Explained: The Future of

Tirzepatide is a once-weekly injection that helps regulate blood sugar levels and reduce hunger, resulting in insignificant weight loss

Nausea is the most commonly reported adverse effect, occurring in approximately 15-20% of patients taking Ozempic and up to 44% of patients taking Wegovy at the 2.4 mg dose during clinical trials

Additionally, the European Commission approved Opdivo plus Yervoy (ipilimumab) for first-line treatment of microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer, further broadening its therapeutic applications

It is crucial to coordinate these steps with a licensed healthcare provider